Business Standard

Thursday, December 19, 2024 | 07:44 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Sebi asks Sun Pharma to explain alleged fund diversion of Rs 42,000 crore

Pharma major calls fund-diversion charges baseless

Sebi starts probe against Sun Pharma, to also reopen insider trading case
Premium

Shrimi Choudhary New Delhi
The Securities and Exchange Board of India (Sebi) has sought an explanation from Sun Pharmaceutical on the alleged fund diversion of Rs 42,000 crore through its key distributor and subsidiary Aditya Mediasales (AML).  

In two letters dated January 28 and February 18, the regulator asked Sun Pharma to furnish a detailed methodology of AML’s operations, along with the agreement between the drugmaker and AML. Sebi also asked Sun Pharma to explain the rationale, terms, and conditions of the advances given to AML. It is a pharma distribution company and is classified as a promoter shareholder by Sun Pharma. It owned

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in